U.S., Feb. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07412080) titled 'EDP167 in Healthy Volunteers and Subjects With Mild Dyslipidemia' on Feb. 02.
Brief Summary: EDP167 is a double-stranded small interfering RNA (siRNA) drug targeting ANGPTL3, which may bring benefits for patients with dyslipidemia conditions. This is the first in human study of EDP167 in health volunteers and subjects with mild dyslipidemia to evaluate the safety and PK/PD profiles of EDP167.
Study Start Date: July 01, 2025
Study Type: INTERVENTIONAL
Condition:
Healthy Adult Male and Female Volunteers
Mild Dyslipidemia
Intervention:
DRUG: EDP167
EDP167 sc injection
DRUG: Placebo
Sterile normal saline (0.9% NaCl) sc injectio...